权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cross-Regulation of Atherosclerosis and Autoimmunity

动脉粥样硬化和自身免疫的交叉调节

基本信息

批准号：
8891486
负责人：
RICK A. WETSEL
金额：
$ 37.43万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-07-15 至 2018-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8891486
关键词：
Affect Animal Model Animals Atherosclerosis Autoantibodies Autoimmune Diseases Autoimmune Process Autoimmunity Biochemical Genetics CD36 gene CD4 Positive T Lymphocytes Cardiovascular Diseases Cardiovascular system Cause of Death Cell Lineage Cells Cellular biology Cerebral Arterial Diseases Cessation of life Chronic Clinical Combat Disorders Coronary artery Data Development Disease Endothelial Cells Epidemiologic Studies Exhibits Frequencies Generations Genetic Goals Health Human Hyperlipidemia Immune Immune response Immune system Immunity Immunologics Incidence Inflammation Interleukin-17 Knowledge Lead Low-Density Lipoproteins Lupus Mediating Mediator of activation protein Metabolism Mission Molecular Mus Pathogenesis Pathway interactions Patients Play Process Psoriasis Public Health Regulation Research Research Personnel Rheumatoid Arthritis Role Signal Transduction Systemic Lupus Erythematosus T cell response T-Lymphocyte TLR4 gene Testing Therapeutic Therapeutic Intervention United States base combat design human FRAP1 protein in vivo innovation insight lipid metabolism new therapeutic target novel novel therapeutic intervention oxidized low density lipoprotein programs receptor response systemic autoimmune disease therapeutic target tool treatment strategy vascular inflammation

项目摘要

DESCRIPTION (provided by applicant): Cardiovascular disease such as atherosclerosis is caused by imbalanced lipid metabolism and represents a leading death cause in United States. Epidemiological studies showed that patients with systemic autoimmune diseases exhibit a higher incidence of atherosclerosis. Conversely, hyperlipidemia has been known to accelerate autoimmune diseases in humans and in animal models. However, there is a considerable gap in our understanding how atherosclerosis impacts the development of the autoimmunity, and vice versa. Our long-term goal is to elucidate novel cross-regulatory mechanisms governing the pathogenesis of atherosclerosis and related autoimmune diseases, which will lead to the development of novel therapeutic interventions for the treatment of these devastating diseases. The primary objective of this R01 application is to investigate the critical cross-regulation between atherosclerosis and autoimmune T cell responses with specific emphasis on Th17 responses. It is our central hypothesis that proatherogenic conditions promote autoimmune Th17 responses through T cell-intrinsic mechanisms which in turn accelerate atherosclerosis. The rationale is that identifying the cross-regulatory mechanisms will enable us to gain multi-disciplinary insights into the pathogenesis of the diseases. Guided by strong preliminary data, this hypothesis will be tested through two specific aims: 1) Determine the role of proatherogenic condition driven Th17 responses in the development of autoimmunity and atherosclerosis; 2) Determine cell-intrinsic regulation of oxidized LDL signaling in Th17 cells. Under the first aim, animal models of autoimmune lupus and atherosclerosis will be used to examine the role of proatherogenic condition-driven Th17 cells in the pathogenesis of these diseases. Under the second aim, biochemical and genetic tools will be used to dissect molecular mechanism for cell intrinsic function of oxidized LDL signaling in promoting Th17 lineage commitment. Our approach is innovative, because it employs interdisciplinary concepts and unique powerful genetic tools to examine mutual pathogenic regulation between atherosclerosis and autoimmune T cell responses by placing hyperlipidemia as an autoimmune mediator. The proposed research is highly significant, because it is anticipated to substantially advance and expand our understanding of how cardiovascular and immune systems cross-talk during the development of atherosclerosis and autoimmunity. Ultimately, such knowledge has the potential to lead to the development of novel immunologic and pharmacologic strategies for the treatment of atherosclerosis and associated autoimmune diseases.

描述（由申请方提供）：心血管疾病（如动脉粥样硬化）是由脂质代谢失衡引起的，是美国的主要死因。流行病学研究表明，系统性自身免疫性疾病患者动脉粥样硬化的发生率较高。相反，高脂血症在人类和动物模型中加速自身免疫性疾病。然而，我们对动脉粥样硬化如何影响自身免疫的发展以及如何影响自身免疫的发展的理解存在相当大的差距。我们的长期目标是阐明动脉粥样硬化和相关自身免疫性疾病发病机制的新的交叉调节机制，这将导致开发新的治疗干预措施来治疗这些毁灭性疾病。该R 01应用的主要目的是研究动脉粥样硬化和自身免疫性T细胞应答之间的关键交叉调节，特别强调Th 17应答。我们的中心假设是，致动脉粥样硬化性疾病通过T细胞内在机制促进自身免疫性Th 17应答，从而加速动脉粥样硬化。其基本原理是，确定交叉调节机制将使我们能够获得多学科的见解疾病的发病机制。在强有力的初步数据的指导下，该假设将通过两个特定目标进行测试：1）确定促动脉粥样硬化条件驱动的Th 17应答在自身免疫和动脉粥样硬化发展中的作用; 2）确定Th 17细胞中氧化LDL信号传导的细胞内在调节。在第一个目标下，将使用自身免疫性狼疮和动脉粥样硬化的动物模型来检查促动脉粥样硬化条件驱动的Th 17细胞在这些疾病的发病机制中的作用。在第二个目标下，将使用生物化学和遗传学工具来剖析氧化LDL信号传导在促进Th 17谱系定型中的细胞内在功能的分子机制。我们的方法是创新的，因为它采用了跨学科的概念和独特的强大的遗传工具，通过将高脂血症作为自身免疫介质来检查动脉粥样硬化和自身免疫T细胞反应之间的相互致病调节。这项研究具有非常重要的意义，因为它有望大大推进和扩大我们对心血管和免疫系统在动脉粥样硬化和自身免疫发展过程中如何相互作用的理解。最终，这些知识有可能导致新的免疫学和药理学策略的发展，用于治疗动脉粥样硬化和相关的自身免疫性疾病。